Safety of consecutive same-day bilateral intravitreal dexamethasone implant (ozurdex)

Conclusion: Consecutive same-day bilateral intravitreal dexamethasone (Ozurdex) is safe and well tolerated. There were no significant complications, and patients preferred continuing bilateral implantation after their initial trial. Same-day treatment may optimize efficiency and decrease patient visits and ultimate treatment burden without compromising patient safety or clinical efficacy.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research

Related Links:

Sure, if something’s portable, easy to use and helps patients and doctors alike, it definitely ticks all our boxes. Does that mean we are going to test it though? Who are we kidding, of course it does! Join us on our journey to learn about the present and future of ophthalmology – and to get to know D-EYE, a new handheld digital retinal camera. Ophthalmology can really profit from telemedicine. Recognising its potential, tech companies started targeting this medical sector, producing more and more interesting apps and devices. So, naturally, we’ve kept our eyes on ophthalmology for the past couple of y...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine Healthcare Design Medical Education Robotics Science Fiction Telemedicine & Smartphones review ophthalmology eye test d-eye Source Type: blogs
CONCLUSION: In summary, these three drugs provide an efficient treatment option with an acceptable benefit-risk ratio for the treatment of naive patients with DME, whether on BCVA or CRT on the first year of treatment. PMID: 32507032 [PubMed - as supplied by publisher]
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research
z-Moreno JM Abstract PURPOSE: To assess the functional and anatomical outcomes of intravitreal dexamethasone implant Ozurdex® in eyes with diabetic macular edema that did not adequately respond to vascular endothelial growth factor inhibitors. METHODS: Multicenter, retrospective, and real-life case series study conducted on consecutive diabetic macular edema patients who underwent treatment with one or more dexamethasone implant injections and were followed up for a minimum of 12 months. Subjects were divided into three groups: I-naïve patients, II-previously treated eyes that received three int...
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research
Publication date: Available online 30 May 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Jia-Kang Wang, Tzu-Lun Huang, Pei-Yao Chang
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
CONCLUSION: In this 6-month retrospective study, intravitreal DEX implant was effective in Taiwanese patients with treatment-naïve DME regardless of vitrectomy status. PMID: 32482606 [PubMed - as supplied by publisher]
Source: J Formos Med Assoc - Category: General Medicine Authors: Tags: J Formos Med Assoc Source Type: research
Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Br J Ophthalmol. 2020 May 27;: Authors: Mansour SE, Kiernan DF, Roth DB, Eichenbaum D, Holekamp NM, Kaba S, Werts E Abstract BACKGROUND: The 0.2 µg/day fluocinolone acetonide (FAc) implant delivers continuous, low-dose, intravitreal corticosteroid for the treatment of diabetic macular oedema (DMO). This ongoing, 3-year, observational clinical trial provides long-term, 'real-world' safety results for the FAc implant in D...
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Br J Ophthalmol Source Type: research
Purpose: To compare the efficacy and safety of intravitreal dexamethasone (DEX) implant versus aflibercept in patients with treatment-naive diabetic macular edema with inflammatory biomarkers. Methods: Ninety-eight eyes of 62 treatment-naive patients with diabetic macular edema with serous retinal detachment and hyperreflective foci were enrolled. Each patient was randomized to receive either aflibercept or DEX implant treatment. The treatment protocol included 3 monthly injections of 2 mg of aflibercept as a loading phase in the anti–vascular endothelial growth factor group and 0.7 mg of DEX implant in the DEX ...
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research
CONCLUSION: Better response to dexamethasone implant in cases with more hyper-reflective dots shows that these hyper-reflective dots can be used as a predictive biomarker. Dexamethasone implant might help in restoring external limiting membrane integrity and resolution of disorganization of retinal inner layers. PMID: 32429696 [PubMed - as supplied by publisher]
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research
ConclusionsDEX implant performed at the time of surgery achieved the same long-term functional and anatomical outcomes compared to a 1-month injection deferral in treating eyes with pre-existing DME that should undergo cataract extraction.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
Conclusions: With fewer than 3 injections per patient over a 3-year period, DEX implant was able to improve anatomic outcomes in DME patients. Only pseudophakic eyes showed also a long lasting functional benefit at 36 months. PMID: 32351722 [PubMed]
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
More News: Dexamethasone | Diabetes | Endocrinology | Eye Implants | Eyes | Opthalmology | Study | Vitamin A